LONDON, UK – October 18, 2011 – Cellnovo was named Best Medtech Fundraiser at the recent 2011 OBN Bioscience Awards, an honour that recognises Cellnovo’s success in raising £30m to advance mobile diabetes management.
“Cellnovo has developed a game changing diabetes management system, and was featured at OBN’s 2011 BioTrinity Conference,”
said Jon Rees, Chief Executive Officer of OBN.
“Cellnovo was an obvious choice to receive the Best MedTech Fundraiser Award and we wish them every success in the commercialization of their system around the world.”
“Cellnovo is very proud of this accomplishment because we added some of the premier investors in Europe to our syndicate, and they are equally passionate about Cellnovo,”
said William McKeon, Chief Executive Officer of Cellnovo.
“They recognised our vision and capability to move beyond convention as we deliver the world’s first mobile diabetes management platform.”
The OBN Annual Bioscience Awards seek to highlight the many great achievements of the bioscience sector in raising funds, making deals and supporting innovation. This year’s Awards placed particular emphasis on the achievements of nominees, like Cellnovo, succeeding despite the challenges of the current financial climate.
“The size of the round and calibre of investors speaks volumes about Cellnovo, the company’s leadership team and its unique offering,”
said Raphael Wisniewski, Partner at Edmond de Rothschild Investment Partners.
“We look for companies that have the potential to transform an industry,”
said Philippe Peltier,Partner at Auriga Partners.
“We feel that Cellnovo is set to bring enormous benefit to diabetics,clinicians, and to health systems worldwide.”
OBN is a not-for-profit business network that provides comprehensive support for its member biotech and medtech companies in the Oxford and South-East England biocluster and the rest of the UK.
Through its delivery of Europe’s fastest growing biopartnering and investment conference, BioTrinity,OBN generates more R&D-company-to-investor interactions than anyone else in Europe.
Cellnovo, an innovative UK-based mobile health company, is committed to bringing greater freedom and ease-of-use to people living with diabetes. The company has developed the industry’s first mobile diabetes management system, which includes a patch pump, a mobile handset with a built-in blood glucose monitor, and an extendable applications set. For more information, please visit www.cellnovo.com.